Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Meta Expands AI Training With Employee Activity Tracking Tools 
NEW ORLEANS, March 04, 2016 -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until May 2, 2016 to file lead plaintiff applications in a securities class action lawsuit against PTC Therapeutics, Inc. (Nasdaq:PTCT), if they purchased the Company’s securities between May 6, 2014 and February 23, 2016, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.
What You May Do
If you purchased shares of PTC and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, call toll-free at 1-877-515-1850 or email KSF Managing Partner Lewis Kahn ([email protected]). If you wish to serve as a lead plaintiff in this class action, you must petition the Court by May 2, 2016.
About the Lawsuit
PTC and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On February 23, 2016, PTC disclosed that it has received a Refuse to File letter from the United States Food and Drug Administration (FDA) regarding PTC’s New Drug Application (NDA) for Translarna for the treatment of muscular dystrophy. PTC further disclosed that the FDA’s Refuse to File letter stated “that the application was not sufficiently complete to permit a substantive review.”
On this news, the price of PTC’s shares plummeted by over 61%.
About Kahn Swick & Foti, LLC
KSF, whose partners include the Former Louisiana Attorney General Charles C. Foti, Jr., is a law firm focused on securities, antitrust and consumer class actions, along with merger & acquisition and breach of fiduciary litigation against publicly traded companies on behalf of shareholders. The firm has offices in New York, California and Louisiana.
To learn more about KSF, you may visit www.ksfcounsel.com.
Contact: Kahn Swick & Foti, LLC Lewis Kahn, Managing Partner [email protected] 1-877-515-1850 206 Covington St. Madisonville, LA 70447
